APO Research
Talk to an analyst

APO RESEARCH · REPORT

Fibromyalgia Therapeutics Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Fibromyalgia Therapeutics Drugs Market Outlook and Growth Opportunities 2026

31 December 2025206 pages

Choose your research edition.

Industry ResearchFibromyalgia Therapeutics Drugs Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal Fibromyalgia Therapeutics Drugs Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Fibromyalgia Therapeutics Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Fibromyalgia Therapeutics Drugs Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Fibromyalgia Therapeutics Drugs Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Fibromyalgia Therapeutics Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Fibromyalgia Therapeutics Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Fibromyalgia Therapeutics Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Fibromyalgia Therapeutics Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Fibromyalgia Therapeutics Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Fibromyalgia Therapeutics Drugs market include Eli Lilly, Pfizer, Zynerba Pharmaceuticals, Tonix Pharmaceuticals Holding Corp. (TNXP), Theravance, Switch Biotech, Pierre Fabre Mdicament, Merck Sharp and Dohme and Meiji Seika, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Fibromyalgia Therapeutics Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Fibromyalgia Therapeutics Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Fibromyalgia Therapeutics Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Fibromyalgia Therapeutics Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Fibromyalgia Therapeutics Drugs Segment by Company

Eli Lilly

Pfizer

Zynerba Pharmaceuticals

Tonix Pharmaceuticals Holding Corp. (TNXP)

Theravance

Switch Biotech

Pierre Fabre Mdicament

Merck Sharp and Dohme

Meiji Seika

Meda

Innovative Med Concepts

Forest Pharmaceuticals, Inc.

Daiichi Sankyo

Daiichi Sankyo

Boehringer Ingelheim GmbH

Actavis

Fibromyalgia Therapeutics Drugs Segment by Type

Cymbalta (Duloxetine)

Savella (Milnacipran)

Lyrica (Pregabalin)

Pancuronium

Others

Fibromyalgia Therapeutics Drugs Segment by Application

Hospital

Clinic

Others

Fibromyalgia Therapeutics Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Fibromyalgia Therapeutics Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Fibromyalgia Therapeutics Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Fibromyalgia Therapeutics Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Fibromyalgia Therapeutics Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Fibromyalgia Therapeutics Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Fibromyalgia Therapeutics Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Fibromyalgia Therapeutics Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Fibromyalgia Therapeutics Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Fibromyalgia Therapeutics Drugs industry.

Chapter 3: Detailed analysis of Fibromyalgia Therapeutics Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Fibromyalgia Therapeutics Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Fibromyalgia Therapeutics Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Fibromyalgia Therapeutics Drugs Industry Trends Table 2. Fibromyalgia Therapeutics Drugs Industry Drivers Table 3. Fibromyalgia Therapeutics Drugs Industry Opportunities and Challenges Table 4. Fibromyalgia Therapeutics Drugs Industry Restraints Table 5. Global Fibromyalgia Therapeutics Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Fibromyalgia Therapeutics Drugs Revenue Share by Company (2021-2026) Table 7. Global Fibromyalgia Therapeutics Drugs Sales Volume by Company (Kg) & (2021-2026) Table 8. Global Fibromyalgia Therapeutics Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Fibromyalgia Therapeutics Drugs Average Price (US$/g) of Company (2021-2026) Table 10. Global Fibromyalgia Therapeutics Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Fibromyalgia Therapeutics Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Fibromyalgia Therapeutics Drugs Company, Product Type & Application Table 13. Global Fibromyalgia Therapeutics Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Fibromyalgia Therapeutics Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Cymbalta (Duloxetine) Table 18. Significant Companies of Savella (Milnacipran) Table 19. Significant Companies of Lyrica (Pregabalin) Table 20. Significant Companies of Pancuronium Table 21. Significant Companies of Others Table 22. Global Fibromyalgia Therapeutics Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (Kg) Table 23. Global Fibromyalgia Therapeutics Drugs Sales Volume by Type (2021-2026) & (Kg) Table 24. Global Fibromyalgia Therapeutics Drugs Sales Volume by Type (2027-2032) & (Kg) Table 25. Global Fibromyalgia Therapeutics Drugs Sales Volume Share by Type (2021-2026) Table 26. Global Fibromyalgia Therapeutics Drugs Sales Volume Share by Type (2027-2032) Table 27. Global Fibromyalgia Therapeutics Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Fibromyalgia Therapeutics Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global Fibromyalgia Therapeutics Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global Fibromyalgia Therapeutics Drugs Sales Value Share by Type (2021-2026) Table 31. Global Fibromyalgia Therapeutics Drugs Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Hospital Table 33. Significant Companies of Clinic Table 34. Significant Companies of Others Table 35. Global Fibromyalgia Therapeutics Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (Kg) Table 36. Global Fibromyalgia Therapeutics Drugs Sales Volume by Application (2021-2026) & (Kg) Table 37. Global Fibromyalgia Therapeutics Drugs Sales Volume by Application (2027-2032) & (Kg) Table 38. Global Fibromyalgia Therapeutics Drugs Sales Volume Share by Application (2021-2026) Table 39. Global Fibromyalgia Therapeutics Drugs Sales Volume Share by Application (2027-2032) Table 40. Global Fibromyalgia Therapeutics Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Fibromyalgia Therapeutics Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Fibromyalgia Therapeutics Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Fibromyalgia Therapeutics Drugs Sales Value Share by Application (2021-2026) Table 44. Global Fibromyalgia Therapeutics Drugs Sales Value Share by Application (2027-2032) Table 45. Global Fibromyalgia Therapeutics Drugs Sales by Region: 2021 VS 2025 VS 2032 (Kg) Table 46. Global Fibromyalgia Therapeutics Drugs Sales by Region (2021-2026) & (Kg) Table 47. Global Fibromyalgia Therapeutics Drugs Sales Market Share by Region (2021-2026) Table 48. Global Fibromyalgia Therapeutics Drugs Sales by Region (2027-2032) & (Kg) Table 49. Global Fibromyalgia Therapeutics Drugs Sales Market Share by Region (2027-2032) Table 50. Global Fibromyalgia Therapeutics Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Fibromyalgia Therapeutics Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Fibromyalgia Therapeutics Drugs Sales Value Share by Region (2021-2026) Table 53. Global Fibromyalgia Therapeutics Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Fibromyalgia Therapeutics Drugs Sales Value Share by Region (2027-2032) Table 55. Global Fibromyalgia Therapeutics Drugs Market Average Price (US$/g) by Region (2021-2026) Table 56. Global Fibromyalgia Therapeutics Drugs Market Average Price (US$/g) by Region (2027-2032) Table 57. Global Fibromyalgia Therapeutics Drugs Sales by Country: 2021 VS 2025 VS 2032 (Kg) Table 58. Global Fibromyalgia Therapeutics Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Fibromyalgia Therapeutics Drugs Sales by Country (2021-2026) & (Kg) Table 60. Global Fibromyalgia Therapeutics Drugs Sales Market Share by Country (2021-2026) Table 61. Global Fibromyalgia Therapeutics Drugs Sales by Country (2027-2032) & (Kg) Table 62. Global Fibromyalgia Therapeutics Drugs Sales Market Share by Country (2027-2032) Table 63. Global Fibromyalgia Therapeutics Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Fibromyalgia Therapeutics Drugs Sales Value Market Share by Country (2021-2026) Table 65. Global Fibromyalgia Therapeutics Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Fibromyalgia Therapeutics Drugs Sales Value Market Share by Country (2027-2032) Table 67. Eli Lilly Company Information Table 68. Eli Lilly Business Overview Table 69. Eli Lilly Fibromyalgia Therapeutics Drugs Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 70. Eli Lilly Fibromyalgia Therapeutics Drugs Product Portfolio Table 71. Eli Lilly Recent Development Table 72. Pfizer Company Information Table 73. Pfizer Business Overview Table 74. Pfizer Fibromyalgia Therapeutics Drugs Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 75. Pfizer Fibromyalgia Therapeutics Drugs Product Portfolio Table 76. Pfizer Recent Development Table 77. Zynerba Pharmaceuticals Company Information Table 78. Zynerba Pharmaceuticals Business Overview Table 79. Zynerba Pharmaceuticals Fibromyalgia Therapeutics Drugs Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 80. Zynerba Pharmaceuticals Fibromyalgia Therapeutics Drugs Product Portfolio Table 81. Zynerba Pharmaceuticals Recent Development Table 82. Tonix Pharmaceuticals Holding Corp. (TNXP) Company Information Table 83. Tonix Pharmaceuticals Holding Corp. (TNXP) Business Overview Table 84. Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Therapeutics Drugs Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 85. Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Therapeutics Drugs Product Portfolio Table 86. Tonix Pharmaceuticals Holding Corp. (TNXP) Recent Development Table 87. Theravance Company Information Table 88. Theravance Business Overview Table 89. Theravance Fibromyalgia Therapeutics Drugs Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 90. Theravance Fibromyalgia Therapeutics Drugs Product Portfolio Table 91. Theravance Recent Development Table 92. Switch Biotech Company Information Table 93. Switch Biotech Business Overview Table 94. Switch Biotech Fibromyalgia Therapeutics Drugs Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 95. Switch Biotech Fibromyalgia Therapeutics Drugs Product Portfolio Table 96. Switch Biotech Recent Development Table 97. Pierre Fabre Mdicament Company Information Table 98. Pierre Fabre Mdicament Business Overview Table 99. Pierre Fabre Mdicament Fibromyalgia Therapeutics Drugs Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 100. Pierre Fabre Mdicament Fibromyalgia Therapeutics Drugs Product Portfolio Table 101. Pierre Fabre Mdicament Recent Development Table 102. Merck Sharp and Dohme Company Information Table 103. Merck Sharp and Dohme Business Overview Table 104. Merck Sharp and Dohme Fibromyalgia Therapeutics Drugs Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 105. Merck Sharp and Dohme Fibromyalgia Therapeutics Drugs Product Portfolio Table 106. Merck Sharp and Dohme Recent Development Table 107. Meiji Seika Company Information Table 108. Meiji Seika Business Overview Table 109. Meiji Seika Fibromyalgia Therapeutics Drugs Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 110. Meiji Seika Fibromyalgia Therapeutics Drugs Product Portfolio Table 111. Meiji Seika Recent Development Table 112. Meda Company Information Table 113. Meda Business Overview Table 114. Meda Fibromyalgia Therapeutics Drugs Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 115. Meda Fibromyalgia Therapeutics Drugs Product Portfolio Table 116. Meda Recent Development Table 117. Innovative Med Concepts Company Information Table 118. Innovative Med Concepts Business Overview Table 119. Innovative Med Concepts Fibromyalgia Therapeutics Drugs Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 120. Innovative Med Concepts Fibromyalgia Therapeutics Drugs Product Portfolio Table 121. Innovative Med Concepts Recent Development Table 122. Forest Pharmaceuticals, Inc. Company Information Table 123. Forest Pharmaceuticals, Inc. Business Overview Table 124. Forest Pharmaceuticals, Inc. Fibromyalgia Therapeutics Drugs Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 125. Forest Pharmaceuticals, Inc. Fibromyalgia Therapeutics Drugs Product Portfolio Table 126. Forest Pharmaceuticals, Inc. Recent Development Table 127. Daiichi Sankyo Company Information Table 128. Daiichi Sankyo Business Overview Table 129. Daiichi Sankyo Fibromyalgia Therapeutics Drugs Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 130. Daiichi Sankyo Fibromyalgia Therapeutics Drugs Product Portfolio Table 131. Daiichi Sankyo Recent Development Table 132. Daiichi Sankyo Company Information Table 133. Daiichi Sankyo Business Overview Table 134. Daiichi Sankyo Fibromyalgia Therapeutics Drugs Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 135. Daiichi Sankyo Fibromyalgia Therapeutics Drugs Product Portfolio Table 136. Daiichi Sankyo Recent Development Table 137. Boehringer Ingelheim GmbH Company Information Table 138. Boehringer Ingelheim GmbH Business Overview Table 139. Boehringer Ingelheim GmbH Fibromyalgia Therapeutics Drugs Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 140. Boehringer Ingelheim GmbH Fibromyalgia Therapeutics Drugs Product Portfolio Table 141. Boehringer Ingelheim GmbH Recent Development Table 142. Actavis Company Information Table 143. Actavis Business Overview Table 144. Actavis Fibromyalgia Therapeutics Drugs Sales (Kg), Value (US$ Million), Price (US$/g) and Gross Margin (2021-2026) Table 145. Actavis Fibromyalgia Therapeutics Drugs Product Portfolio Table 146. Actavis Recent Development Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Fibromyalgia Therapeutics Drugs Distributors List Table 150. Fibromyalgia Therapeutics Drugs Customers List Table 151. Research Programs/Design for This Report Table 152. Authors List of This Report Table 153. Secondary Sources Table 154. Primary Sources List of Figures Figure 1. Fibromyalgia Therapeutics Drugs Product Image Figure 2. Global Fibromyalgia Therapeutics Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Fibromyalgia Therapeutics Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Fibromyalgia Therapeutics Drugs Sales (2021-2032) & (Kg) Figure 5. Global Fibromyalgia Therapeutics Drugs Sales Average Price (US$/g) & (2021-2032) Figure 6. Global Fibromyalgia Therapeutics Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Cymbalta (Duloxetine) Image Figure 10. Savella (Milnacipran) Image Figure 11. Lyrica (Pregabalin) Image Figure 12. Pancuronium Image Figure 13. Others Image Figure 14. Global Fibromyalgia Therapeutics Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (Kg) Figure 15. Global Fibromyalgia Therapeutics Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global Fibromyalgia Therapeutics Drugs Sales Volume Share by Type (2021-2032) Figure 17. Global Fibromyalgia Therapeutics Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Fibromyalgia Therapeutics Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Fibromyalgia Therapeutics Drugs Sales Value Share by Type (2021-2032) Figure 20. Hospital Image Figure 21. Clinic Image Figure 22. Others Image Figure 23. Global Fibromyalgia Therapeutics Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (Kg) Figure 24. Global Fibromyalgia Therapeutics Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Fibromyalgia Therapeutics Drugs Sales Volume Share by Application (2021-2032) Figure 26. Global Fibromyalgia Therapeutics Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Fibromyalgia Therapeutics Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Fibromyalgia Therapeutics Drugs Sales Value Share by Application (2021-2032) Figure 29. Global Fibromyalgia Therapeutics Drugs Sales by Region: 2021 VS 2025 VS 2032 (Kg) Figure 30. Global Fibromyalgia Therapeutics Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Fibromyalgia Therapeutics Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Fibromyalgia Therapeutics Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Fibromyalgia Therapeutics Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. North America Fibromyalgia Therapeutics Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Fibromyalgia Therapeutics Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Fibromyalgia Therapeutics Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Fibromyalgia Therapeutics Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Fibromyalgia Therapeutics Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Fibromyalgia Therapeutics Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. South America Fibromyalgia Therapeutics Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Fibromyalgia Therapeutics Drugs Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Fibromyalgia Therapeutics Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Fibromyalgia Therapeutics Drugs Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Fibromyalgia Therapeutics Drugs Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • Cymbalta (Duloxetine)
  • Savella (Milnacipran)
  • Lyrica (Pregabalin)
  • Pancuronium
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Eli Lilly
  • Pfizer
  • Zynerba Pharmaceuticals
  • Tonix Pharmaceuticals Holding Corp. (TNXP)
  • Theravance
  • Switch Biotech
  • Pierre Fabre Mdicament
  • Merck Sharp and Dohme
  • Meiji Seika
  • Meda
  • Innovative Med Concepts
  • Forest Pharmaceuticals, Inc.
  • Daiichi Sankyo
  • Daiichi Sankyo
  • Boehringer Ingelheim GmbH
  • Actavis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Fibromyalgia Therapeutics Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Fibromyalgia Therapeutics Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Fibromyalgia Therapeutics Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Fibromyalgia Therapeutics Drugs Market Dynamics
  1. 2.1 Fibromyalgia Therapeutics Drugs Industry Trends
  2. 2.2 Fibromyalgia Therapeutics Drugs Industry Drivers
  3. 2.3 Fibromyalgia Therapeutics Drugs Industry Opportunities and Challenges
  4. 2.4 Fibromyalgia Therapeutics Drugs Industry Restraints
3 Fibromyalgia Therapeutics Drugs Market by Company
  1. 3.1 Global Fibromyalgia Therapeutics Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Fibromyalgia Therapeutics Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Fibromyalgia Therapeutics Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Fibromyalgia Therapeutics Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Fibromyalgia Therapeutics Drugs Company Ranking (2024-2026)
  6. 3.6 Global Fibromyalgia Therapeutics Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Fibromyalgia Therapeutics Drugs Company Product Type and Application
  8. 3.8 Global Fibromyalgia Therapeutics Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Fibromyalgia Therapeutics Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Fibromyalgia Therapeutics Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Fibromyalgia Therapeutics Drugs Market by Type
  1. 4.1 Fibromyalgia Therapeutics Drugs Type Introduction
  2. 4.1.1 Cymbalta (Duloxetine)
  3. 4.1.2 Savella (Milnacipran)
  4. 4.1.3 Lyrica (Pregabalin)
  5. 4.1.4 Pancuronium
  6. 4.1.5 Others
  7. 4.2 Global Fibromyalgia Therapeutics Drugs Sales Volume by Type
  8. 4.2.1 Global Fibromyalgia Therapeutics Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Fibromyalgia Therapeutics Drugs Sales Volume by Type (2021-2032)
  10. 4.2.3 Global Fibromyalgia Therapeutics Drugs Sales Volume Share by Type (2021-2032)
  11. 4.3 Global Fibromyalgia Therapeutics Drugs Sales Value by Type
  12. 4.3.1 Global Fibromyalgia Therapeutics Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Fibromyalgia Therapeutics Drugs Sales Value by Type (2021-2032)
  14. 4.3.3 Global Fibromyalgia Therapeutics Drugs Sales Value Share by Type (2021-2032)
5 Fibromyalgia Therapeutics Drugs Market by Application
  1. 5.1 Fibromyalgia Therapeutics Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Fibromyalgia Therapeutics Drugs Sales Volume by Application
  6. 5.2.1 Global Fibromyalgia Therapeutics Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Fibromyalgia Therapeutics Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Fibromyalgia Therapeutics Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Fibromyalgia Therapeutics Drugs Sales Value by Application
  10. 5.3.1 Global Fibromyalgia Therapeutics Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Fibromyalgia Therapeutics Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Fibromyalgia Therapeutics Drugs Sales Value Share by Application (2021-2032)
6 Fibromyalgia Therapeutics Drugs Regional Sales and Value Analysis
  1. 6.1 Global Fibromyalgia Therapeutics Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Fibromyalgia Therapeutics Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Fibromyalgia Therapeutics Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Fibromyalgia Therapeutics Drugs Sales by Region (2027-2032)
  5. 6.3 Global Fibromyalgia Therapeutics Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Fibromyalgia Therapeutics Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Fibromyalgia Therapeutics Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Fibromyalgia Therapeutics Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Fibromyalgia Therapeutics Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Fibromyalgia Therapeutics Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Fibromyalgia Therapeutics Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Fibromyalgia Therapeutics Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Fibromyalgia Therapeutics Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Fibromyalgia Therapeutics Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Fibromyalgia Therapeutics Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Fibromyalgia Therapeutics Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Fibromyalgia Therapeutics Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Fibromyalgia Therapeutics Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Fibromyalgia Therapeutics Drugs Sales Value Share by Country, 2025 VS 2032
7 Fibromyalgia Therapeutics Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Fibromyalgia Therapeutics Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Fibromyalgia Therapeutics Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Fibromyalgia Therapeutics Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Fibromyalgia Therapeutics Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Fibromyalgia Therapeutics Drugs Sales by Country (2027-2032)
  6. 7.4 Global Fibromyalgia Therapeutics Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Fibromyalgia Therapeutics Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Fibromyalgia Therapeutics Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Fibromyalgia Therapeutics Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Fibromyalgia Therapeutics Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Fibromyalgia Therapeutics Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eli Lilly
  2. 8.1.1 Eli Lilly Company Information
  3. 8.1.2 Eli Lilly Business Overview
  4. 8.1.3 Eli Lilly Fibromyalgia Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Eli Lilly Fibromyalgia Therapeutics Drugs Product Portfolio
  6. 8.1.5 Eli Lilly Recent Developments
  7. 8.2 Pfizer
  8. 8.2.1 Pfizer Company Information
  9. 8.2.2 Pfizer Business Overview
  10. 8.2.3 Pfizer Fibromyalgia Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Fibromyalgia Therapeutics Drugs Product Portfolio
  12. 8.2.5 Pfizer Recent Developments
  13. 8.3 Zynerba Pharmaceuticals
  14. 8.3.1 Zynerba Pharmaceuticals Company Information
  15. 8.3.2 Zynerba Pharmaceuticals Business Overview
  16. 8.3.3 Zynerba Pharmaceuticals Fibromyalgia Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Zynerba Pharmaceuticals Fibromyalgia Therapeutics Drugs Product Portfolio
  18. 8.3.5 Zynerba Pharmaceuticals Recent Developments
  19. 8.4 Tonix Pharmaceuticals Holding Corp. (TNXP)
  20. 8.4.1 Tonix Pharmaceuticals Holding Corp. (TNXP) Company Information
  21. 8.4.2 Tonix Pharmaceuticals Holding Corp. (TNXP) Business Overview
  22. 8.4.3 Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Therapeutics Drugs Product Portfolio
  24. 8.4.5 Tonix Pharmaceuticals Holding Corp. (TNXP) Recent Developments
  25. 8.5 Theravance
  26. 8.5.1 Theravance Company Information
  27. 8.5.2 Theravance Business Overview
  28. 8.5.3 Theravance Fibromyalgia Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Theravance Fibromyalgia Therapeutics Drugs Product Portfolio
  30. 8.5.5 Theravance Recent Developments
  31. 8.6 Switch Biotech
  32. 8.6.1 Switch Biotech Company Information
  33. 8.6.2 Switch Biotech Business Overview
  34. 8.6.3 Switch Biotech Fibromyalgia Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Switch Biotech Fibromyalgia Therapeutics Drugs Product Portfolio
  36. 8.6.5 Switch Biotech Recent Developments
  37. 8.7 Pierre Fabre Mdicament
  38. 8.7.1 Pierre Fabre Mdicament Company Information
  39. 8.7.2 Pierre Fabre Mdicament Business Overview
  40. 8.7.3 Pierre Fabre Mdicament Fibromyalgia Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Pierre Fabre Mdicament Fibromyalgia Therapeutics Drugs Product Portfolio
  42. 8.7.5 Pierre Fabre Mdicament Recent Developments
  43. 8.8 Merck Sharp and Dohme
  44. 8.8.1 Merck Sharp and Dohme Company Information
  45. 8.8.2 Merck Sharp and Dohme Business Overview
  46. 8.8.3 Merck Sharp and Dohme Fibromyalgia Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Merck Sharp and Dohme Fibromyalgia Therapeutics Drugs Product Portfolio
  48. 8.8.5 Merck Sharp and Dohme Recent Developments
  49. 8.9 Meiji Seika
  50. 8.9.1 Meiji Seika Company Information
  51. 8.9.2 Meiji Seika Business Overview
  52. 8.9.3 Meiji Seika Fibromyalgia Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Meiji Seika Fibromyalgia Therapeutics Drugs Product Portfolio
  54. 8.9.5 Meiji Seika Recent Developments
  55. 8.10 Meda
  56. 8.10.1 Meda Company Information
  57. 8.10.2 Meda Business Overview
  58. 8.10.3 Meda Fibromyalgia Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Meda Fibromyalgia Therapeutics Drugs Product Portfolio
  60. 8.10.5 Meda Recent Developments
  61. 8.11 Innovative Med Concepts
  62. 8.11.1 Innovative Med Concepts Company Information
  63. 8.11.2 Innovative Med Concepts Business Overview
  64. 8.11.3 Innovative Med Concepts Fibromyalgia Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Innovative Med Concepts Fibromyalgia Therapeutics Drugs Product Portfolio
  66. 8.11.5 Innovative Med Concepts Recent Developments
  67. 8.12 Forest Pharmaceuticals, Inc.
  68. 8.12.1 Forest Pharmaceuticals, Inc. Company Information
  69. 8.12.2 Forest Pharmaceuticals, Inc. Business Overview
  70. 8.12.3 Forest Pharmaceuticals, Inc. Fibromyalgia Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Forest Pharmaceuticals, Inc. Fibromyalgia Therapeutics Drugs Product Portfolio
  72. 8.12.5 Forest Pharmaceuticals, Inc. Recent Developments
  73. 8.13 Daiichi Sankyo
  74. 8.13.1 Daiichi Sankyo Company Information
  75. 8.13.2 Daiichi Sankyo Business Overview
  76. 8.13.3 Daiichi Sankyo Fibromyalgia Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Daiichi Sankyo Fibromyalgia Therapeutics Drugs Product Portfolio
  78. 8.13.5 Daiichi Sankyo Recent Developments
  79. 8.14 Daiichi Sankyo
  80. 8.14.1 Daiichi Sankyo Company Information
  81. 8.14.2 Daiichi Sankyo Business Overview
  82. 8.14.3 Daiichi Sankyo Fibromyalgia Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Daiichi Sankyo Fibromyalgia Therapeutics Drugs Product Portfolio
  84. 8.14.5 Daiichi Sankyo Recent Developments
  85. 8.15 Boehringer Ingelheim GmbH
  86. 8.15.1 Boehringer Ingelheim GmbH Company Information
  87. 8.15.2 Boehringer Ingelheim GmbH Business Overview
  88. 8.15.3 Boehringer Ingelheim GmbH Fibromyalgia Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Boehringer Ingelheim GmbH Fibromyalgia Therapeutics Drugs Product Portfolio
  90. 8.15.5 Boehringer Ingelheim GmbH Recent Developments
  91. 8.16 Actavis
  92. 8.16.1 Actavis Company Information
  93. 8.16.2 Actavis Business Overview
  94. 8.16.3 Actavis Fibromyalgia Therapeutics Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Actavis Fibromyalgia Therapeutics Drugs Product Portfolio
  96. 8.16.5 Actavis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Fibromyalgia Therapeutics Drugs Value Chain Analysis
  2. 9.1.1 Fibromyalgia Therapeutics Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Fibromyalgia Therapeutics Drugs Sales Mode & Process
  6. 9.2 Fibromyalgia Therapeutics Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Fibromyalgia Therapeutics Drugs Distributors
  9. 9.2.3 Fibromyalgia Therapeutics Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst